An interventional study of AI-assisted comprehensive management system in Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition), sponsored by The First Affiliated Hospital of Xinxiang Medical College. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by The First Affiliated Hospital of Xinxiang Medical College · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 417 studies in Diabetes Mellitus with a site in China — 100 open to participants now, 117 under way, 11 of them phase 3. Diabetes Mellitus · China.
Among the 417 studies in Diabetes Mellitus with a site in China, this one is the 10th largest by planned enrollment of the 280 interventional ones that give a count, is one of 45 that started in 2025, is one of 118 with no phase, reaches primary completion later than 81 of the 116 other live ones, and was the 385th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →100 of the 417 studies in Diabetes Mellitus with a site in China are open now. Recruiting first, the newest first:
China Medical University, China · Sites in China
Ages 50–75
CSL Behring · Sites in China
Ages 18+
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
417 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 25 · Phase 3 41 · Phase 4 52
First in 2002; this study’s year is marked. 45 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 143 across the 280 interventional studies, 605 across the 137 observational. Of the 204 that completed or were terminated, 47 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 417 have an industry lead sponsor. The 10 most frequent:
The First Affiliated Hospital of Xinxiang Medical College is the lead sponsor of 42 studies on the registry; 38 are open to participants now.
The First Affiliated Hospital of Xinxiang Medical College has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
19 of the studies in Diabetes Mellitus with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06309082First Affiliated Hospital of Wenzhou Medical UniversityAssessing Diabetic Foot Ulcer Microcirculation With High-frequency Contrast Enhanced Ultrasound | 2026-12 |
| NCT05105321Tang YidaCardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP) | 2026-12 |
| NCT07489482Jiangsu HengRui Medicine Co., Ltd.A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection | 2026-12 |
| NCT06959784China-Japan Friendship HospitalAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) | 2026-12-31 |
| NCT06958640China-Japan Friendship HospitalDa Qing Offspring Study | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 417 studies in Diabetes Mellitus with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Combined with the digital whole process management data pool, a multi-modal data fusion framework is developed, and an AI model is established to realize risk stratification and personalized treatment Recommendation and dynamic prognosis prediction; validation of whole-process management based on multimodal digital fusion AI-aided decision support system through prospective non-randomized controlled interventional study The effect on survival, complication control and utilization of medical resources in patients with comorbid malignant tumors.
The title of this study is"The Impact of Multimodal Digital Fusion AI-Assisted Decision Support System-Based Comprehensive Management on Clinical Outcomes in County-Level Patients with Comorbid Cancer: A prospective non-randomized controlled interventional study", to evaluate the impact of full-course management based on a multimodal digital fusion AI-assisted decision support system on the clinical outcomes of county-level oncologic comorbid patients through a prospective non-randomized controlled interventional study. The study plans to enroll 5,000 patients with pathologically confirmed malignancies and at least one comorbid condition (diabetes, hypertension, etc.) , in the first stage, the epidemiological characteristics of co-morbidity and its impact on prognosis, treatment response and quality of life were analyzed In the second phase, patients with comorbid pulmonary malignancies were selected to compare the clinical effects of the voluntary whole-process management group (including personalized intervention such as nutritional screening and dynamic monitoring) and the conventional treatment group, the third stage integrates multi-center Electronic Medical Records, genomic data, wearable device monitoring and other multi-modal data to construct an AI decision-making system, developing risk stratification, personalized treatment recommendation, and dynamic prognostic prediction models, finally, the differences in core indicators such as survival rate (PFS, OS) , complication control and medical resource efficiency between AI-assisted management and traditional mode were compared. This study realizes the integrated intervention of in-hospital and out-of-hospital through digital whole-process management, which is expected to provide an AI-driven precise decision support paradigm for primary medical institutions and improve the efficiency of comprehensive management of tumor comorbidity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For patients with comorbid pulmonary malignancies who have been included, the registration process is guided by the management platform. Researchers will use digital management throughout The platform carries out screening assessment and Comprehensive Evaluation of nutrition, exercise, psychology and symptoms of the subjects, and the system will be combined with the patient's disease and treatment Information, intelligent management of the whole project. The clinician can review the protocol in the light of the patient's disease status and give the full management instructions Case to patient side.
Other: AI-assisted comprehensive management system
Patients who are not willing to accept the whole program will only be followed up, and will receive standard clinical management without AI-assisted digital platform support. Patients will receive conventional treatment. In the data analysis phase, subjects were stratified to explore the feasibility and effectiveness of digital whole-course management in patients with oncological comorbidities.
Precision Risk Stratification and personalized treatment recommendation through AI models may improve the suitability of treatment regimens and thus reduce the incidence of antineoplastic therapy-related adverse effects (e.g. , reduction of chemotherapy toxicity through nutritional intervention) , and improve the efficacy of chemotherapy, and prolonged progression-free survival (PFS) and overall survival (OS)
Progression-free survival (PFS)
Progression-free survival (PFS) : the time from randomization (or study enrollment) to the observation of disease progression or the occurrence of death from any cause. This period was assessed every 6-8 weeks using RECIST 1.1 criteria.
Time frame: 24 months
Overall survival (OS)
Overall survival (OS) : the time from study enrollment to death from any cause from any cause, every 3 months during treatment, and every 3 months after the end of treatment. The patients were followed up at 6 months and the cause of death was recorded.
Time frame: 24 months
Comorbidity control rate.
Comorbidity control rate: the proportion of comorbidities achieving guideline-recommended control targets during the study period; stratified criteria should be established based on specific comorbidity types.
Time frame: 24 months
Quality of life(QLQ-C30).
Quality of life: changes in scores at baseline, on-treatment, and follow-up were assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30 scale, between-group differences
Time frame: 24 months
Medical resource consumption index.
Medical resource consumption index: Comparing DRG-adjusted medical resource consumption indices between two groups.
Time frame: 24 months
Adherence to AI system interventions.
Adherence to AI Interventions: 1. In-Hospital Rate - Percentage of inpatients completing AI-recommended actions (e.g., nutritional screening, real-time monitoring). 2. Out-of-Hospital Completion Rate: Percentage of discharged/outpatients adhering to AI-guided care (e.g., telehealth, wearable data tracking). Enables precise evaluation of AI-driven care across clinical settings.
Time frame: 24 months
Plan to share: No — Data security and privacy protection measures.
Start is estimated for Aug 2025; primary completion for May 2027, 20 months later.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 20 months is close to that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Xinxiang Medical College